As a potential antitumor drug, UA was able to inhibit the enrichment of the lung CSC population by inhibiting the activation of Jak2-Stat3, in turn reversing the resistance of lung cancer cells to cisplatin. The gene discussed is JAK2; the disease is lung carcinoma.